AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36335573
Drug: benzoate 500
RxNorm normalized name: aminobenzoate 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benzoate 500 (fixed 500 mg/day)
Trial: 36335573
Drug: benzoate 750
RxNorm normalized name: imidazole-2-hydroxybenzoate 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benzoate 750 (500 mg/day for the first 4 weeks, 750 mg/day from the 5th week)
Trial: 32556619
Drug: Patient-specific titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific titanium onlay implant
Trial: 32317617
Drug: Everolimus with
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus with Reduced Calcineurin Inhibitor Exposure
Trial: 34971525
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg i.v. infusion over 40 min)
Trial: 34971525
Drug: Ketamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (10 mg/kg i.p.)
Trial: 34971525
Drug: (2R,6R)‐HNK (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2R,6R)‐HNK (10 mg/kg i.p.)
Trial: 33063096
Drug: Nurse-led self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led self-management and self-assessment program including educational video and home-based exercises, with monthly reporting of ASDAS/BASDAI scores.
Trial: 32073608
Drug: Low-calorie breakfast
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie breakfast (11% of daily kilocalorie requirement)
Trial: 32073608
Drug: High-calorie dinner
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie dinner (69% of daily kilocalorie requirement)
Trial: 34406315
Drug: 5.25% NaOCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.25% NaOCI solution
Trial: 34406315
Drug: 5.25% NaOCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.25% NaOCI gel
Trial: 32419594
Drug: 8-mg intramuscular
RxNorm normalized name: ISOtretinoin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg intramuscular injections of a non-viral DNA plasmid
Trial: 32419594
Drug: 16-mg intramuscular
RxNorm normalized name: afamelanotide 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-mg intramuscular injections of a non-viral DNA plasmid
Trial: 35751777
Drug: Levothyroxine (LT4)
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (LT4) solid formulation, 200 mcg orally administered at 08:00 h
Trial: 35751777
Drug: Levothyroxine (LT4)
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (LT4) liquid formulation, 200 mcg orally administered at 08:00 h
Trial: 32659160
Drug: Simulated Treatment
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated Treatment Comparison (STC)
Trial: 33890449
Drug: Costoclavicular block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Costoclavicular block (CC)
Trial: 35761262
Drug: L‐HIIT (supervised)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐HIIT (supervised)
Trial: 33085801
Drug: Tailored pharmacist-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored pharmacist-led intervention based on adherence barriers (forgetfulness, lack of knowledge, lack of motivation, other drug-related problems)
Trial: 34705785
Drug: Patient-specific implants
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific implants
Trial: 33346683
Drug: Colchicine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (25 nmol/L)
Trial: 35476143
Drug: Galcanezumab 300
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Galcanezumab 300 mg subcutaneously every 4 weeks
Trial: 35025542
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and interpersonal psychotherapy (IPT)
Trial: 33852248
Drug: Oral sarecycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sarecycline (once-daily, weight-based dosing)
Trial: 33852248
Drug: Control (multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (multivitamin tablet)
Trial: 32852531
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg, weeks 1 and 3)
Trial: 32852531
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus Ipilimumab (Ipilimumab 1 mg/kg, week 1 only)
Trial: 35685982
Drug: Allograft patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allograft patch augmentation
Trial: 35685982
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CC subgroup)
Trial: 35685982
Drug: Allograft group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allograft group (CC subgroup)
Trial: 36213912
Drug: Fear-focused Self-compassion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fear-focused Self-compassion Therapy
Trial: 34818379
Drug: Voriconazole treatment
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole treatment
Trial: 32951999
Drug: Sublingual sufentanil
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual sufentanil tablet system
Trial: 32951999
Drug: Nurse-controlled continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-controlled continuous morphine infusion
Trial: 32886131
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug treatment (Control)
Trial: 36286675
Drug: Remaxol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remaxol (400 ml/day)
Trial: 36286675
Drug: Heptral (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptral (800 mg/day)
Trial: 32915426
Drug: Dingkun Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dingkun Pill (7 g daily for 21 days, followed by 7 drug-free days)
Trial: 32915426
Drug: Diane‐35 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane‐35 (1 tablet daily for 21 days, followed by 7 drug-free days)
Trial: 32915426
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (Dingkun Pill and Diane‐35)
Trial: 35005040
Drug: Meaning-centered play
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meaning-centered play intervention, implemented in twelve 45-minute sessions, twice a week for six weeks.
Trial: 32646743
Drug: Deferral of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferral of statin therapy
Trial: 33236676
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy problems (adverse drug reactions)
Trial: 32898792
Drug: Switch maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch maintenance chemotherapy (pemetrexed 500 mg/m2 d1, 22 for non-squamous cell carcinoma; gemcitabine 1,150 mg/m2 d1, 8, 22 for squamous cell carcinoma)
Trial: 32898792
Drug: Switch maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch maintenance chemotherapy
Trial: 35953245
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin two times per day
Trial: 35060404
Drug: Single-session Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session Acceptance and Commitment Therapy intervention (<3 hours)
Trial: 32554365
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection of 20 mL 0.5% bupivacaine HCl (100 mg) after implantation
Trial: 32554365
Drug: Combined periarticular
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined periarticular injection of 20 mL 0.5% bupivacaine HCl (100 mg) and incisional injection of 10 mL 0.5% bupivacaine HCl (50 mg)
Trial: 35285906
Drug: 1.50 g
RxNorm normalized name: Dimethicone 1.50 g in 150 mL TOPICAL EMULSION [VITAMIN B5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.50 g · kg‐1 · d‐1 protein plus multinutrient beverage (NUT)
Trial: 35285906
Drug: 0.900 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.900 g · kg‐1 · d‐1 protein plus placebo (PLA)
Trial: 33381794
Drug: Glucose supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose supplementation 3 times daily
Trial: 33381794
Drug: Fructose supplementation
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose supplementation 3 times daily
Trial: 33203954
Drug: ASP4345 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP4345 (3, 15, 50, and 150 mg; n = 9 each dose)
Trial: 33317824
Drug: Sunlight treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunlight treatment
Trial: 33935152
Drug: Digital therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital therapy group (12-week home-based digitally assisted rehabilitation program with 13 face-to-face sessions)
Trial: 33935152
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy group (30 sessions of conventional face-to-face physical therapy)
Trial: 32181830
Drug: Nonaerosol spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonaerosol spray sunscreen
Trial: 35586820
Drug: Warming Yang,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming Yang, tonifying kidney, and removing arthralgia therapy
Trial: 35586820
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment not specified)
Trial: 35668532
Drug: 3-week multimodal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-week multimodal, individualized prehabilitation program including exercise therapy, nutritional intervention, mobility or balance training, and psychosocial interventions and medical assessment, supervised 5 times/week for 3 weeks.
Trial: 32846841
Drug: Bidirectional barbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bidirectional barbed suture (Stratafix1-0 for joint capsule, Stratafix2-0 for subcutaneous, Stratafix3-0 for intracutaneous)
Trial: 32846841
Drug: Traditional absorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional absorbable suture (Ethicon VICRYL* Plus 1-0 for joint capsule, Ethicon VICRYL* Plus 2-0 for subcutaneous, staples for skin)
Trial: 34664106
Drug: CAF-6 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-6 (6 mg/kg caffeine)
Trial: 34664106
Drug: CAF-3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-3 (3 mg/kg caffeine)
Trial: 32589244
Drug: Analgesic treatment
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic treatment only (Group A)
Trial: 32589244
Drug: Chest physiotherapy
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest physiotherapy and analgesic treatment (Group B)
Trial: 33068791
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with a prescribed dose of 35 Gy in five fractions
Trial: 32474728
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (both doses)
Trial: 33413311
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron therapy (4 weeks before surgery)
Trial: 33413311
Drug: Autologous whole
RxNorm normalized name: Autologous whole blood product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous whole blood therapy (2 units collected 4 and 2 weeks before surgery)
Trial: 33413311
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron therapy
Trial: 33413311
Drug: Autologous whole
RxNorm normalized name: Autologous whole blood product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous whole blood therapy
Trial: 36000037
Drug: High-dose intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intranasal desmopressin (40 μg)
Trial: 36000037
Drug: Low-dose intranasal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intranasal desmopressin (20 μg)
Trial: 33142037
Drug: Sinbaglustat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinbaglustat (10 to 2000 mg single doses; 30 to 1000 mg twice daily for 7 days)
Trial: 35723814
Drug: Ruyi Zhenbao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruyi Zhenbao Pills (RZPs) for 4 weeks
Trial: 35867804
Drug: istaroxime 1.0‐1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: istaroxime 1.0‐1.5 μg/kg/min
Trial: 32898271
Drug: Recombinant HA
RxNorm normalized name: Recombinant haemagglutinin protein-strain A (H3N2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HA vaccine (rHA)
Trial: 32898271
Drug: Egg-derived inactivated
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg-derived inactivated influenza vaccine (IIV)
Trial: 32898271
Drug: Cell-derived inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell-derived inactivated influenza vaccine (IIV)
Trial: 33991711
Drug: Anti-VEGF injections
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF injections (as-needed regimen)
Trial: 34358954
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 300 mg glycerol monolaurate/kg
Trial: 34840945
Drug: e-Yoga intervention
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-Yoga intervention administered via e-Yoga modalities
Trial: 36320174
Drug: Betahistine 24
RxNorm normalized name: betahistine 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 24 mg every 12 h for 90 days
Trial: 36320174
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets every 12 h for 90 days
Trial: 35717595
Drug: ECHO (carer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECHO (carer skills intervention) added to treatment as usual (TAU)
Trial: 33597136
Drug: Increased physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased physical activity (daily walking)
Trial: 32900508
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (15 mg isobaric bupivacaine 0.5% with 0.5 ml normal saline 0.9%)
Trial: 36694242
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (weekly pick-up with monthly check-ups)
Trial: 33638741
Drug: Screw augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screw augmentation with bone cement
Trial: 33638741
Drug: No screw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No screw augmentation
Trial: 34495285
Drug: Online 1-day
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online 1-day cognitive behavioral therapy (CBT)-based workshop plus usual care (n = 202)
Trial: 33508495
Drug: COC users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC users (Microgynon®) during day 15-16 of pill consumption (PC2)
Trial: 33508495
Drug: COC users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC users (Microgynon®) during day 2-3 of pill consumption (PC1)
Trial: 32043148
Drug: Supervised rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised rehabilitation intervention (physical therapy and occupational therapy-based interventions)
Trial: 32410849
Drug: Pioglitazone Metformin
RxNorm normalized name: metformin / pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone Metformin complex (PM)
Trial: 32801009
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in triglycerides by 1 mmol/L (89 mg/dL)
Trial: 32459348
Drug: e-coach-guided, web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-coach-guided, web-based self-help intervention based on cognitive behavioral therapy
Trial: 34726293
Drug: Ethosuximide 500
RxNorm normalized name: Ethosuximide
DrugBank: Ethosuximide (DB00593)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethosuximide 500 mg t.i.d along with mebeverine 135 mg t.i.d
Trial: 34726293
Drug: Mebeverine 135
RxNorm normalized name: mebeverine 135 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine 135 mg t.i.d
Trial: 33041091
Drug: ω‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFA therapy (2 g daily for 3 months)
Trial: 32791681
Drug: Tonifying Kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonifying Kidney and Invigorating Brain acupuncture plus standardized physical rehabilitation treatment
Trial: 32791681
Drug: Standardized physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physical rehabilitation treatment
Trial: 32813051
Drug: COVID Impact
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID Impact Survey administered during the pandemic
Trial: 34080498
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) paracetamol
Trial: 34080498
Drug: Modified-release (MR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release (MR) paracetamol
Trial: 34080498
Drug: Both IR
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both IR and MR paracetamol
Trial: 35482532
Drug: Avacopan 30
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan 30 mg twice daily for 52 weeks
Trial: 36087921
Drug: Virtual simulation-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual simulation-based training program for etonogestrel subdermal contraceptive implant insertion and removal
Trial: 32056721
Drug: Low-dose indacaterol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose indacaterol acetate/mometasone furoate 150/80 μg once daily
Trial: 32056721
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 200 μg once daily
Trial: 34600129
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy plus adoptive transfer of allogeneic γδ T cells (HCC, Group B; ICC, Group D)
Trial: 34600129
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy (HCC, Group A; ICC, Group C)
Trial: 34600129
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy plus adoptive transfer of allogeneic γδ T cells (HCC, Group B)
Trial: 34600129
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy (HCC, Group A)
Trial: 34600129
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy plus adoptive transfer of allogeneic γδ T cells (ICC, Group D)
Trial: 34600129
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy (ICC, Group C)
Trial: 32945567
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy and therapeutic alliance feedback
Trial: 36256926
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE, 0.625 mg/d)
Trial: 36256926
Drug: CEE +
RxNorm normalized name: Conjugated Estrogen Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE + medroxyprogesterone acetate (MPA; 2.5 mg/d)
Trial: 36454738
Drug: Talazoparib vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib vs Standard therapy
Trial: 33853099
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy for 30 minutes
Trial: 33565303
Drug: Educational programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational programme and actual insulin injection demonstration (physician-led sample insulin injection using an insulin pen)